High-Dose Convalescent Plasma for Treatment of Severe COVID-19

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  De Santis, Gil C. ; Oliveira, Luciana Correa ; Garibaldi, Pedro M.M. ; Almado, Carlos E.L. ; Croda, Julio ; Arcanjo, Ghislaine G.A. ; Oliveira, Érika A.F. ; Tonacio, Adriana C. ; Langhi, Dante M. ; Bordin, José O. ; Gilio, Renato N. ; Palma, Leonardo C. ; Santos, Elaine V. ; Haddad, Simone K. ; Prado, Benedito P.A. ; Pontelli, Marjorie Cornejo ; Gomes, Rogério ; Miranda, Carlos H. ; Martins, Maria Auxiliadora ; Covas, Dimas T. ; Arruda, Eurico ; Fonseca, Benedito A.L. ; Calado, Rodrigo T.
• Description:
  To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.
• Subjects:
  Covid-19/Therapy Humans Immunization, Passive / Adverse Effects Plasma Sars-Cov-2 Treatment Outcome
• Source:
  Emerg Infect Dis. 2022; 28(3):548-555
• Pubmed ID:
  35081022
• Pubmed Central ID:
  PMC8888205
• Document Type:
  Journal Article
• Place as Subject:
  Brazil
• Volume:
  28
• Issue:
  3
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:7577a4dd2611117c8053ed42fb6a5fb0d6b61c01bbc9b320294834c33571f364
• Download URL:
  https://stacks.cdc.gov/view/cdc/115231/cdc_115231_DS1.pdf
• File Type:
  [PDF - 1.39 MB ]